GlobeNewsWire
29 May 2026, 10:50 UTC · 16w ago
Verdict
Headline takes no side. We score PHVS +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 71% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Pharvaris expects topline data from its CHAPTER-3 pivotal Phase 3 study of deucrictibant extended-release tablets in the third quarter of 2026.
More positive than 92% of claims this week
Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsules as an on-demand treatment for HAE attacks.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 76% of claims this week
Pharvaris will present one oral presentation and seven flash talk/poster presentations at the EAACI Annual Congress in June 2026.
More positive than 40% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The company has multiple abstracts accepted for presentation at a major medical congress, indicating positive scientific progress and visibility.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+20.6%
Price agrees with the score
$36.02 vs $29.86 close before publication (May 28) · not market-adjusted
PHVS chart →